Schonfeld Strategic Advisors’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-16,228
| Closed | -$2.08M | – | 2223 |
|
|
2025
Q2 | $2.08M | Sell |
16,228
-29,072
| -64% | -$3.02M | 0.01% | 965 |
|
|
2025
Q1 | $4.01M | Buy |
45,300
+32,100
| +243% | +$3.13M | 0.02% | 612 |
|
|
2024
Q4 | $1.15M | Sell |
13,200
-46,158
| -78% | -$4.23M | 0.01% | 1055 |
|
|
2024
Q3 | $5.49M | Buy |
59,358
+55,408
| +1,403% | +$5.5M | 0.04% | 511 |
|
|
2024
Q2 | $426K | Buy |
+3,950
| New | +$395K | ﹤0.01% | 1559 |
|
|
2023
Q2 | – | Sell |
-69,629
| Closed | -$3.13M | – | 2156 |
|
|
2023
Q1 | $3.13M | Buy |
+69,629
| New | +$3.14M | 0.03% | 570 |
|
|
2022
Q4 | – | Sell |
-26,484
| Closed | -$1.74M | – | 2611 |
|
|
2022
Q3 | $1.74M | Buy |
+26,484
| New | +$1.7M | 0.01% | 937 |
|
|
2021
Q4 | – | Sell |
-19,818
| Closed | -$2.04M | – | 2159 |
|
|
2021
Q3 | $2.04M | Buy |
+19,818
| New | +$1.85M | 0.02% | 709 |
|
|
2021
Q1 | – | Sell |
-27,137
| Closed | -$3.04M | – | 1813 |
|
|
2020
Q4 | $3.04M | Buy |
27,137
+20,722
| +323% | +$2.18M | 0.04% | 509 |
|
|
2020
Q3 | $595K | Buy |
+6,415
| New | +$494K | 0.01% | 859 |
|
|
2020
Q1 | – | Sell |
-3,074
| Closed | -$246K | – | 1163 |
|
|
2019
Q4 | $246K | Sell |
3,074
-30,726
| -91% | -$2.3M | 0.01% | 1070 |
|
|
2019
Q3 | $2.48M | Sell |
33,800
-109,700
| -76% | -$9.48M | 0.07% | 272 |
|
|
2019
Q2 | $13.5M | Buy |
143,500
+21,500
| +18% | +$1.77M | 0.48% | 48 |
|
|
2019
Q1 | $9.77M | Buy |
+122,000
| New | +$9.02M | 0.34% | 71 |
|
|
2018
Q1 | – | Sell |
-13,588
| Closed | -$1.02M | – | 767 |
|
|
2017
Q4 | $1.02M | Buy |
+13,588
| New | +$956K | 0.08% | 303 |
|
|
2017
Q2 | – | Sell |
-17,849
| Closed | -$714K | – | 617 |
|
|
2017
Q1 | $714K | Buy |
+17,849
| New | +$639K | 0.07% | 311 |
|
Other funds holding BPMC
IA
HNB
Schonfeld Strategic Advisors's BPMC Position: Q3 2025 in Review
Schonfeld Strategic Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 16,228 shares — an estimated $2.08M sold.
Schonfeld Strategic Advisors first reported a position in BPMC in Q1 2017 and held it in 16 quarters. The position peaked at $13.5M in Q2 2019. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Schonfeld Strategic Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 16,228 Blueprint Medicines shares in Q3 2025, an estimated $2.08M.
- Schonfeld Strategic Advisors first reported a position in Blueprint Medicines in Q1 2017 and held it in 16 quarters.
- Schonfeld Strategic Advisors's Blueprint Medicines position peaked at $13.5M in Q2 2019.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.